<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65135">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02257970</url>
  </required_header>
  <id_info>
    <org_study_id>7781</org_study_id>
    <nct_id>NCT02257970</nct_id>
  </id_info>
  <brief_title>Placebo-controlled Lymphedema Study for Arm or Leg Lymphedema</brief_title>
  <acronym>PB</acronym>
  <official_title>Case-controlled, Open Label Therapeutic Trial for Unilateral or Bilateral Lymphedema of Arm or Leg.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the effectiveness of a study drug versus placebo in the treatment of
      lymphedema to the untreated condition, in the same individual..
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compares the effectiveness of a study drug versus placebo in the treatment of
      lymphedema to the untreated condition, in the same individual. This will be accomplished by
      obtaining four biopsies (small pieces of skin from your arm or leg), before treatment and
      after treatment. We will try to determine how the study drug affects the body tissue.
      Patients who participate in this study will be randomly assigned (like flipping a coin) to
      receive either the study drug or a placebo, which is an inactive substance which may
      resemble an active agent, but has no medical value. Every participant will have a 50:50
      chance of receiving the study drug.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    study endpoints met
  </why_stopped>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amelioration of cutaneous histological architecture</measure>
    <time_frame>at 4 months</time_frame>
    <description>Change in cutaneous histological architecture noted by examination of skin punch biopsy samples, normal and lymphedema samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bioimpedance readings</measure>
    <time_frame>at 4 months</time_frame>
    <description>If unilateral, a significant improvement in bioimpedance readings of the affected arm or leg compared to those of the normal arm or leg, at study end.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Limb volume</measure>
    <time_frame>at 4 months</time_frame>
    <description>Assessment of limb volume of the affected arm or leg at study end.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Lymphedema</condition>
  <arm_group>
    <arm_group_label>oral anti-inflammatory drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anti-inflammatory oral drug, 1 capsule, three times/day, for 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 1 capsule, three times/day, for 4 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral anti-inflammatory drug</intervention_name>
    <description>1 capsule, three times a day, for four months</description>
    <arm_group_label>oral anti-inflammatory drug</arm_group_label>
    <other_name>anti-inflammatory oral medication</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule, three times a day, for four months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a history of lymphedema of one or more limbs (unilateral or bilateral), with a
             duration of &gt; 6 months.

        Exclusion Criteria:

          -  Patients with active cancer, infection or bleeding tendency will be excluded.

          -  We will also exclude patients with medical contraindications to NSAIDs, including
             history of allergies, know gastrointestinal intolerance, or other serious systemic
             illness (e.g., renal failure, hepatic dysfunction, congestive heart failure,
             neurological or psychological impairment) that would impair the patients' ability to
             participate.

          -  Minors (&lt;18 years of age) *&gt;90 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley G Rockson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://stanfordhealthcare.org/medical-clinics/center-lymphatic-venous-disorders.html</url>
    <description>Stanford Health Care: Center for Lymphatic and Venous Disorders</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>August 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Stanley Rockson</investigator_full_name>
    <investigator_title>Allan and Tina Neill Professor of Lymphatic Research and Medicine; Professor of Cardiovascular Medicine</investigator_title>
  </responsible_party>
  <keyword>Lymphedema</keyword>
  <keyword>edema</keyword>
  <keyword>swelling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>grouped data may be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
